Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects

por Jani, Rajendra H., Kansagra, Kevinkumar, Jain, Mukul R., Patel, Harilal
Publicado 2013

Non-clinical safety evaluation of a novel pharmaceutical salt, rosuvastatin ethanolamine, in Wistar rats

por Vaghasiya, Jigneshkumar, Patel, Satyam, Patel, Sudhir, Kadam, Shekhar, Ranvir, Ramchandra, Patel, Harilal, Sundar, Rajesh, Jain, Mukul
Publicado 2019

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Asce...

por Parmar, Deven V., Kansagra, Kevinkumar A., Momin, Taufik, Patel, Hardik B., Jansari, Gaurav A., Bhavsar, Jay, Shah, Chintan, Patel, Jayesh M., Ghoghari, Ashok, Barot, Ajay, Sharma, Bhavesh, Viswanathan, Kasinath, Patel, Harilal V., Jain, Mukul R.
Publicado 2022

Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volu...

por Kansagra, Kevinkumar A., Parmar, Deven, Jani, Rajendra H., Srinivas, Nuggehally R., Lickliter, Jason, Patel, Harilal V., Parikh, Devang P., Heading, Heather, Patel, Hardik B., Gupta, Rahul J., Shah, Chintan Y., Patel, Maulik R., Dholakia, Vyom N., Sukhadiya, Raghav, Jain, Mukul R., Parmar, Krupi V., Barot, Kinjal
Publicado 2017